ClinicalTrials.gg
CompletedNCT01149655ATTAIN 266Updated Apr 2, 2015Results posted

Efficacy & Safety Study of Oral Aripiprazole in Adolescents With Schizophrenia

A Phase 3 interventional study of Aripiprazole and Aripiprazole in Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 52 sites in 7 countries. Open to participants aged 13 Years to 17 Years. Per ClinicalTrials.gov, last updated 2015-04-02.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
252
Allocation
Randomized
Ages
13 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 126 studies testing aripiprazole in Schizophrenia — 4 open to participants now, 4 under way, 1 of them phase 3. Aripiprazole · Schizophrenia.

Enrollment
41st of 125
252 · median 130
Started
2011
with 3 others
Phase 3
34 of 126
1 open now
Registered
65th of 126
by date
Lead sponsor
44 of 126
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 126 studies testing aripiprazole in Schizophrenia, this one is the 41st largest by enrollment of the 125 interventional ones that give a count, is one of 4 that started in 2011, is one of 34 in phase 3, and was the 65th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

4 of the 126 studies testing aripiprazole in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About aripiprazole

Aripiprazole: first FDA approval 2002 (ABILIFY), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 13 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 126 studies testing aripiprazole in Schizophrenia, or all of them as a file.
02

Study summary

This will be a randomized, double-blind, placebo-controlled study consisting of a screening period, a conversion phase (Phase 1), a stabilization phase (Phase 2), and a double-blind maintenance treatment phase (Phase 3), and a follow up period.

Subjects may be either outpatients or inpatients between screening and through the time they reach stabilization at the end of Phase 2; hospitalization is not a study requirement. However, eligible subjects must be outpatients at the beginning of Phase 3.

Subjects will be assessed weekly during Phase 1, weekly for the first 4 weeks of Phase 2 and 3, and biweekly for the remaining weeks during each of Phases 2 and 3. Subjects will be encouraged to call the investigators with any exacerbation of psychotic symptoms and/or any tolerability issues. The investigator will also have the option to phone the subjects and their guardian(s) at any time to ensure clinical stability.

A data monitoring committee (DMC) will provide oversight for safety monitoring and reviewing the interim analysis. One interim analysis is planned after 75% of the total expected number of impending relapse events (28 events) are achieved and will be conducted by an independent data analysis center. The DMC will make a recommendation about stopping or continuing the study based on safety and efficacy reviews. The results of the interim analysis and individual subject data will remain blinded to the sponsor during the course of the study until the DMC determines that the study will conclude based on the results of the interim analysis, or the study is completed after 37 endpoint events.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Adolescent
  • Schizophrenia
04

Who can participate

Ages eligible
13 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with a current diagnosis of schizophrenia, and a history of the illness (diagnosis or symptoms) for at least 6 months prior to screening.
  • Subjects who have shown previous response to antipsychotic treatment (other than clozapine) and are not resistant to treatment with other antipsychotics.
  • Subjects who are currently being treated with oral or depot antipsychotics other than clozapine.
  • Subjects with a history of relapse and/or exacerbation of symptoms when they are not receiving antipsychotic treatment.

Exclusion criteria

Exclusion Criteria:

  • Subjects with a current diagnosis other than schizophrenia.
  • Subjects with delirium, dementia, amnesia or other cognitive disorders; subjects with psychotic symptoms that are better accounted for by another general medical condition(s) or direct effect of a substance (i.e., medication, illicit drug use, etc.).
  • Subjects with attention deficit disorder or attention deficit hyperactivity disorder and/or subjects who were on a stimulant treatment for any period of time over the last one year prior to screening.
  • Subjects with any neurodevelopmental disorder, except Tourette's syndrome.
  • Subjects experiencing acute depressive symptoms within the past 30 days prior to screening.
  • Subjects who meet the DSM-IV-TR criteria for substance dependence (including alcohol and benzodiazepines, but excluding caffeine and nicotine) within the past 180 days prior to screening.
  • Subjects who have epilepsy, a history of seizures (except for a single childhood febrile seizure or post-traumatic seizure), or a history of severe head trauma or stroke, or have a history or current evidence of other unstable medical conditions.
  • Subjects with a history of subclinical hypothyroidism (TSH ≥ 4.0 mIU/L), known hypothyroidism or hyperthyroidism (unless the condition has been stabilized with medication for at least 90 days prior to entry into Phase 1 or Phase 2).
  • Subjects who have a medical history of uncontrolled diabetes, labile or unstable diabetes (brittle diabetes), newly diagnosed diabetes, or abnormal blood glucose levels.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
252 participants (actual)

Study arms

  • Experimental
    Phase 1

    Aripiprazole (2-mg, 5-mg, 10-mg, 15-mg, 20-mg, 25-mg or 30-mg)

    Drug: Aripiprazole

  • Experimental
    Phase 2

    Aripiprazole (2-mg, 5-mg, 10-mg, 15-mg, 20-mg, 25-mg or 30-mg)

    Drug: Aripiprazole

  • Placebo comparator
    Phase 3

    Aripiprazole (10-mg, 15-mg, 20-mg, 25-mg or 30-mg) or placebo

    Drug: Aripiprazole

Interventions

  • Aripiprazole (2-mg, 5-mg, 10-mg, 15-mg, 20-mg, 25-mg or 30-mg)

  • Aripiprazole (10-mg, 15-mg, 20-mg, 25-mg or 30-mg)

06

What researchers measure

Primary outcomes

  1. Overall Relapse Rate (in Percent) From Randomization to Exacerbation of Psychotic Symptoms/Impending Relapse.

    The primary efficacy variable was overall relapse rate from randomization, as assessed by Clinical Global Impression of Improvement (CGI-I) score ≥5, Positive and Negative Syndrome Scale (PANSS) scores for hostility or uncooperativeness ≥5, or ≥20% increase in PANSS Total Score. Impending relapse was defined as meeting any of the following 5 criteria: 1) CGI-I score of ≥ 5 (minimally worse) and increase in individual PANSS items to a score \> 4 with an absolute increase of ≥ 2 on that specific item or absolute increase of ≥ 4 on the combined 4 PANSS items (conceptual disorganization, hallucinatory behavior, suspiciousness, unusual thought content). OR 2) CGI-I score of 6 or 7 (much or very much worse) OR 3) Hospitalization due to worsening of illness OR 4) Any suicidal behavior or answers of "yes" to Questions 4 or 5 on the suicidal ideation section of the C-SSRS OR 5) Violent or aggressive behavior resulting in clinically significant injury.

    Time frame: Baseline to Week 52/End of Phase 3 visit.

Secondary outcomes

  1. Percentage of Participants Meeting Exacerbation of Psychotic Symptoms/Impending Relapse Criteria.

    Impending relapse was defined as meeting any of the following 5 criteria: 1) CGI-I score of ≥ 5 (minimally worse) and increase in individual PANSS items to a score \> 4 with an absolute increase of ≥ 2 on that specific item or absolute increase of ≥ 4 on the combined 4 PANSS items. OR 2) CGI-I score of 6 or 7 (much or very much worse) OR 3) Hospitalization due to worsening of illness OR 4) Any suicidal behavior or answers of "yes" to Questions 4 or 5 on the suicidal ideation section of the C-SSRS OR 5) Violent or aggressive behavior resulting in clinically significant injury.

    Time frame: Baseline to Week 52/End of Phase 3 visit.

  2. Percentage of Responders in Each Treatment Group.

    Percentage of responders in each treatment group (i.e, response defined as meeting stability criteria). Participants stabilized on aripiprazole (trial drug) within the approved dose range of 10 to 30 mg/day and are tolerable based on clinical judgment.

    Time frame: Baseline to Week 52/End of Phase 3 visit

  3. Percentage of Participants Who Had Achieved Remission.

    Percentage of participants who had achieved remission, where remission was defined as a score of ≤ 3 on each of the following specific PANSS items, maintained for a period of 6 months: delusions, unusual thought content, hallucinatory behavior, conceptual disorganization, mannerisms/ posturing, blunted affect, social withdrawal, and lack of spontaneity.

    Time frame: Baseline to Week 52/End of Phase 3 visit.

  4. Percentage of Participants Who Discontinued Due to All Reasons Other Than Sponsor Discontinued Study.

    Percentage of participants discontinued due to all reasons other than sponsor discontinued study were noted.

    Time frame: Baseline to Week 52/End of Phase 3 visit

Other outcomes

  1. Mean Change From Baseline to Endpoint in PANSS Total Score.

    The PANSS consisted of 3 subscales with a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicates (absence of symptoms) and a score of 7 indicates (extremely severe symptoms). The symptom constructs for each subscale were positive subscale, negative subscale and general psychopathology subscale. The PANSS Total Score ranged from 30 (best possible outcome) to 210 (worst possible outcome).

    Time frame: Baseline to Week 52/End of Phase 3 visit.

  2. Mean Change From Baseline to Endpoint in CGI-S Score.

    The severity of illness for each participant was rated using the CGI-S scale. To assess CGI-s, the Investigator answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices included: 0= not assessed; 1= normal, not at all ill; 2= borderline mentally ill; 3= mildly ill; 4= moderately ill; 5= markedly ill; 6= severely ill; and 7= among the most extremely ill participants.

    Time frame: Baseline to Week 52/End of Phase 3 visit.

  3. Mean CGI-I Score at Endpoint.

    Baseline for the double-blind maintenance phase was defined as the last visit with available data in the stabilization phase, and the CGI-I scale was completed prior to or on the first dose date in the double-blind maintenance phase. Response choices included: 0 = not assessed; 1 = very much improved,;2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; and 7 = very much worse.

    Time frame: Baseline to Week 52/End of Phase 3 visit.

  4. Mean Change From Baseline to Endpoint in PANSS Positive Subscale.

    The PANSS consisted of 3 subscales were a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicated (absence of symptoms) and a score of 7 indicated (extremely severe symptoms). The 7 positive symptom constructs were delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. The PANSS Total Score ranged from 30 (best possible outcome) to 210 (worst possible outcome).

    Time frame: Baseline to Week 52/End of Phase 3 visit.

  5. Mean Change From Baseline to Endpoint in PANSS Negative Subscale.

    The PANSS consisted of 3 subscales were a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicated (absence of symptoms) and a score of 7 indicated (extremely severe symptoms). The 7 negative symptom constructs were blunted affect, emotional withdrawal, poor rapport, passive apathetic withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation and stereotyped thinking. The PANSS Total Score ranged from 30 (best possible outcome) to 210 (worst possible outcome).

    Time frame: Baseline to Week 52/End of Phase 3 visit.

  6. Mean Change From Baseline to Endpoint in Children's Global Assessment Scale (CGAS).

    The CGAS was developed by Schaffer and colleagues to provide a global measure of severity of disturbance in children and adolescents. The CGAS is a rating scale for evaluating the overall functioning of a participant during a specified time period on a continuum from psychological or psychiatric sickness to health. The CGAS is a valid and reliable tool for rating a child's general level of functioning on a health-illness continuum. CGAS score (range 1-100) was a single item score for rating a child's general level of functioning on a health-illness continuum, with higher scores represented better functioning.

    Time frame: Baseline to Week 52/End of Phase 3 visit.

07

Results

Posted Apr 2, 2015

Participant flow

A Phase 3 randomized, double-blind, placebo-controlled study consisted of screening period, conversion (Period 1), stabilization (Period 2), double-blind maintenance treatment (Period 3) and a follow-up period to evaluate efficacy and safety of aripiprazole (10-30 mg/day) compared to placebo in adolescent participants with schizophrenia.

Period 1 - Conversion Phase
Participant flow — Period 1 - Conversion Phase
MilestoneAripiprazole-Conversion PhaseAripiprazole-Stabilization PhaseAripiprazole-Double Blind (DB) MaintenanceAripiprazole-Placebo-DB Maintenance
Started186000
Completed168000
Not completed18000
Withdrew: Lost to follow-up1000
Withdrew: Sponsor discontinued trial4000
Withdrew: Met withdrawal criteria1000
Withdrew: Physician decision2000
Withdrew: Withdrawal by subject7000
Withdrew: Adverse event without relapse3000
Period 2-Stabilization Phase
Participant flow — Period 2-Stabilization Phase
MilestoneAripiprazole-Conversion PhaseAripiprazole-Stabilization PhaseAripiprazole-Double Blind (DB) MaintenanceAripiprazole-Placebo-DB Maintenance
Started018300
Completed014600
Not completed03700
Withdrew: Sponsor discontinued trial01600
Withdrew: Met withdrawal criteria0700
Withdrew: Physician decision0300
Withdrew: Withdrawal by subject0500
Withdrew: Adverse event without relapse0600
Period 3-DB Maintenance Phase
Participant flow — Period 3-DB Maintenance Phase
MilestoneAripiprazole-Conversion PhaseAripiprazole-Stabilization PhaseAripiprazole-Double Blind (DB) MaintenanceAripiprazole-Placebo-DB Maintenance
Started009848
Completed00156
Not completed008342
Withdrew: Sponsor discontinued trial005819
Withdrew: Physician decision0010
Withdrew: Withdrawal by subject0044
Withdrew: Adverse event without relapse0011
Withdrew: Relapse with ae001918

Outcome measures

PrimaryOverall Relapse Rate (in Percent) From Randomization to Exacerbation of Psychotic Symptoms/Impending Relapse.

The primary efficacy variable was overall relapse rate from randomization, as assessed by Clinical Global Impression of Improvement (CGI-I) score ≥5, Positive and Negative Syndrome Scale (PANSS) scores for hostility or uncooperativeness ≥5, or ≥20% increase in PANSS Total Score. Impending relapse was defined as meeting any of the following 5 criteria: 1) CGI-I score of ≥ 5 (minimally worse) and increase in individual PANSS items to a score \> 4 with an absolute increase of ≥ 2 on that specific item or absolute increase of ≥ 4 on the combined 4 PANSS items (conceptual disorganization, hallucinatory behavior, suspiciousness, unusual thought content). OR 2) CGI-I score of 6 or 7 (much or very much worse) OR 3) Hospitalization due to worsening of illness OR 4) Any suicidal behavior or answers of "yes" to Questions 4 or 5 on the suicidal ideation section of the C-SSRS OR 5) Violent or aggressive behavior resulting in clinically significant injury.

Time frame:
Baseline to Week 52/End of Phase 3 visit.
Reported as:
Number · relapse rate(percentage of participants)
Overall Relapse Rate (in Percent) From Randomization to Exacerbation of Psychotic Symptoms/Impending Relapse.
relapse rate(percentage of participants)Aripiprazole-Double Blind MaintenancePlacebo-Double Blind Maintenance
Overall Relapse Rate (in Percent) From Randomization to Exacerbation of Psychotic Symptoms/Impending Relapse.19.3937.50
Statistical analysis
  • Aripiprazole-Double Blind Maintenance vs Placebo-Double Blind Maintenance · Log Rank · p = 0.0161 · Cox proportional hazard: 0.461 · 95% CI 0.242 to 0.879Hazard ratios and their 95% confidence intervals were derived from the Cox Proportional Hazard model with treatment as term. Hazard ratio \< 1 is in favor of oral aripiprazole 10-30 mg group for superiority test.
SecondaryPercentage of Participants Meeting Exacerbation of Psychotic Symptoms/Impending Relapse Criteria.

Impending relapse was defined as meeting any of the following 5 criteria: 1) CGI-I score of ≥ 5 (minimally worse) and increase in individual PANSS items to a score \> 4 with an absolute increase of ≥ 2 on that specific item or absolute increase of ≥ 4 on the combined 4 PANSS items. OR 2) CGI-I score of 6 or 7 (much or very much worse) OR 3) Hospitalization due to worsening of illness OR 4) Any suicidal behavior or answers of "yes" to Questions 4 or 5 on the suicidal ideation section of the C-SSRS OR 5) Violent or aggressive behavior resulting in clinically significant injury.

Time frame:
Baseline to Week 52/End of Phase 3 visit.
Reported as:
Number · percentage of participants
Percentage of Participants Meeting Exacerbation of Psychotic Symptoms/Impending Relapse Criteria.
percentage of participantsAripiprazole-Double Blind MaintenancePlacebo-Double Blind Maintenance
CGI-I + PANSS16.3333.33
CGI-I of 6 or 711.2225.00
Hospitalization1.0210.42
Suicidal Behavior1.020.00
Violent Behavior4.0810.42
SecondaryPercentage of Responders in Each Treatment Group.

Percentage of responders in each treatment group (i.e, response defined as meeting stability criteria). Participants stabilized on aripiprazole (trial drug) within the approved dose range of 10 to 30 mg/day and are tolerable based on clinical judgment.

Time frame:
Baseline to Week 52/End of Phase 3 visit
Reported as:
Number · percentage of participants
Percentage of Responders in Each Treatment Group.
percentage of participantsAripiprazole-Double Blind MaintenancePlacebo-Double Blind Maintenance
Week 1 (Arirpiprazole N= 95, Placebo N= 45)96.897.8
Week 2 (N= 91, 46)92.395.7
Week 3 (N= 86, 45)93.086.7
Week 4 (N= 91, 43)93.490.7
Week 6 (N= 87, 41)90.892.7
Week 8 (N= 82, 38)97.689.5
Week 10 (N= 74, 32)94.693.8
Week 12 (N= 71, 30)94.493.3
Week 14 (N= 68, 26)94.192.3
Week 16 (N= 65, 25)96.996.0
Week 18 (N= 59, 23)94.991.3
Week 20 (N= 57, 23)94.791.3
Week 22 (N= 55, 21)92.795.2
Week 24 (N= 51, 19)98.0100.0
Week 26 (N= 48, 19)97.9100.0
Week 28 (N= 42, 17)97.6100.0
Week 30 (N= 40, 16)95.0100.0
Week 32 (N= 39, 16)94.993.8
Week 34 (N= 38, 14)94.7100.0
Week 36 (N= 36, 15)94.4100.0
Week 38 (N= 33, 12)100.0100.0
Week 40 (N= 29, 11)100.0100.0
Week 42 (N= 27, 11)100.0100.0
Week 44 (N= 21, 8)100.0100.0
Week 46 (N= 18, 8)88.9100.0
Week 48 (N= 17, 8)94.1100.0
Week 50 (N= 17, 6)88.2100.0
Week 52 (N= 14, 7)100.0100.0
Last Visit (N= 98, 48)77.664.6
Statistical analysis
  • Aripiprazole-Double Blind Maintenance vs Placebo-Double Blind Maintenance · Chi-squared · p = 0.0962p-value was derived using Chi-square test.
SecondaryPercentage of Participants Who Had Achieved Remission.

Percentage of participants who had achieved remission, where remission was defined as a score of ≤ 3 on each of the following specific PANSS items, maintained for a period of 6 months: delusions, unusual thought content, hallucinatory behavior, conceptual disorganization, mannerisms/ posturing, blunted affect, social withdrawal, and lack of spontaneity.

Time frame:
Baseline to Week 52/End of Phase 3 visit.
Reported as:
Number · percentage of participants
Percentage of Participants Who Had Achieved Remission.
percentage of participantsAripiprazole-Double Blind MaintenancePlacebo-Double Blind Maintenance
Percentage of Participants Who Had Achieved Remission.43.842.1
Statistical analysis
  • Aripiprazole-Double Blind Maintenance vs Placebo-Double Blind Maintenance · Chi-squared · p = 0.9025p-value was derived using Chi-square test.
SecondaryPercentage of Participants Who Discontinued Due to All Reasons Other Than Sponsor Discontinued Study.

Percentage of participants discontinued due to all reasons other than sponsor discontinued study were noted.

Time frame:
Baseline to Week 52/End of Phase 3 visit
Reported as:
Number · percentage of participants
Percentage of Participants Who Discontinued Due to All Reasons Other Than Sponsor Discontinued Study.
percentage of participantsAripiprazole-Double Blind MaintenancePlacebo-Double Blind Maintenance
Percentage of Participants Who Discontinued Due to All Reasons Other Than Sponsor Discontinued Study.25.5147.92
Statistical analysis
  • Aripiprazole-Double Blind Maintenance vs Placebo-Double Blind Maintenance · Log Rank · p = 0.0076p-value was derived from the log-rank tests.
Other pre-specifiedMean Change From Baseline to Endpoint in PANSS Total Score.

The PANSS consisted of 3 subscales with a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicates (absence of symptoms) and a score of 7 indicates (extremely severe symptoms). The symptom constructs for each subscale were positive subscale, negative subscale and general psychopathology subscale. The PANSS Total Score ranged from 30 (best possible outcome) to 210 (worst possible outcome).

Time frame:
Baseline to Week 52/End of Phase 3 visit.
Reported as:
Mean · Units on a scale
Mean Change From Baseline to Endpoint in PANSS Total Score.
Units on a scaleAripiprazole-Double Blind MaintenancePlacebo-Double Blind Maintenance
Week 1 (Aripiprazole N= 95, Placebo N= 45)0.22 ± 5.62-0.27 ± 4.66
Week 20.09 ± 5.77-0.58 ± 6.01
Week 3-0.36 ± 6.411.81 ± 9.66
Week 4-0.64 ± 6.901.56 ± 11.13
Week 6-1.20 ± 8.282.92 ± 13.39
Week 8-1.62 ± 9.203.71 ± 14.29
Week 10-1.20 ± 9.613.90 ± 14.80
Week 12-0.19 ± 10.574.52 ± 16.17
Week 14-0.18 ± 11.065.50 ± 17.21
Week 16-0.78 ± 11.725.56 ± 17.33
Week 18-0.68 ± 12.305.57 ± 17.24
Week 20-0.57 ± 12.466.06 ± 17.84
Week 22-0.31 ± 12.376.10 ± 18.98
Week 24-0.36 ± 12.365.92 ± 19.22
Week 26-0.88 ± 12.415.81 ± 19.65
Week 28-0.85 ± 12.525.65 ± 19.82
Week 30-0.96 ± 12.715.60 ± 19.96
Week 32-0.99 ± 12.746.21 ± 20.43
Week 34-1.12 ± 13.055.79 ± 19.85
Week 36-0.55 ± 13.045.40 ± 20.20
Week 38-0.84 ± 13.175.21 ± 20.27
Week 40-0.92 ± 13.215.10 ± 20.34
Week 42-1.14 ± 13.264.94 ± 20.36
Week 44-0.96 ± 13.324.88 ± 20.47
Week 46-1.02 ± 13.354.83 ± 20.54
Week 48-0.99 ± 13.344.67 ± 20.72
Week 50-1.19 ± 13.434.71 ± 20.66
Week 52-1.31 ± 13.474.79 ± 20.60
Other pre-specifiedMean Change From Baseline to Endpoint in CGI-S Score.

The severity of illness for each participant was rated using the CGI-S scale. To assess CGI-s, the Investigator answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices included: 0= not assessed; 1= normal, not at all ill; 2= borderline mentally ill; 3= mildly ill; 4= moderately ill; 5= markedly ill; 6= severely ill; and 7= among the most extremely ill participants.

Time frame:
Baseline to Week 52/End of Phase 3 visit.
Reported as:
Mean · Units on a scale
Mean Change From Baseline to Endpoint in CGI-S Score.
Units on a scaleAripiprazole-Double Blind MaintenancePlacebo-Double Blind Maintenance
Week 1 (Aripiprazole N= 94, Placebo N= 45)0.01 ± 0.230.02 ± 0.34
Week 2 (N= 97, 48)0.00 ± 0.320.02 ± 0.44
Week 30.01 ± 0.400.13 ± 0.64
Week 40.03 ± 0.440.10 ± 0.69
Week 60.04 ± 0.520.15 ± 0.77
Week 80.04 ± 0.630.19 ± 0.79
Week 100.02 ± 0.710.25 ± 0.81
Week 120.05 ± 0.770.31 ± 0.85
Week 140.03 ± 0.780.35 ± 1.04
Week 160.02 ± 0.830.33 ± 1.06
Week 180.04 ± 0.830.35 ± 1.06
Week 200.05 ± 0.850.40 ± 1.12
Week 220.08 ± 0.870.38 ± 1.14
Week 240.06 ± 0.880.35 ± 1.18
Week 260.05 ± 0.890.35 ± 1.18
Week 280.05 ± 0.920.33 ± 1.19
Week 300.04 ± 0.910.33 ± 1.19
Week 320.04 ± 0.920.31 ± 1.21
Week 340.05 ± 0.930.29 ± 1.22
Week 360.07 ± 0.950.29 ± 1.22
Week 380.07 ± 0.950.29 ± 1.22
Week 400.07 ± 0.950.29 ± 1.22
Week 420.06 ± 0.940.29 ± 1.22
Week 440.08 ± 0.950.31 ± 1.21
Week 460.07 ± 0.950.31 ± 1.21
Week 480.06 ± 0.940.29 ± 1.22
Week 500.05 ± 0.950.27 ± 1.25
Week 520.05 ± 0.950.29 ± 1.22
Other pre-specifiedMean CGI-I Score at Endpoint.

Baseline for the double-blind maintenance phase was defined as the last visit with available data in the stabilization phase, and the CGI-I scale was completed prior to or on the first dose date in the double-blind maintenance phase. Response choices included: 0 = not assessed; 1 = very much improved,;2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; and 7 = very much worse.

Time frame:
Baseline to Week 52/End of Phase 3 visit.
Reported as:
Mean · Units on a scale
Mean CGI-I Score at Endpoint.
Units on a scaleAripiprazole-Double Blind MaintenancePlacebo-Double Blind Maintenance
Baseline2.40 ± 0.802.52 ± 0.82
Week 1 (Aripiprazole N= 94, Placebo N= 45)3.49 ± 0.843.51 ± 0.84
Week 2 (N= 97, 48)3.48 ± 0.883.52 ± 0.95
Week 33.47 ± 0.893.63 ± 1.06
Week 43.60 ± 0.923.60 ± 1.20
Week 63.53 ± 1.003.73 ± 1.30
Week 83.46 ± 1.093.83 ± 1.45
Week 103.38 ± 1.133.90 ± 1.49
Week 123.45 ± 1.193.96 ± 1.44
Week 143.44 ± 1.234.04 ± 1.56
Week 163.32 ± 1.254.00 ± 1.57
Week 183.35 ± 1.294.02 ± 1.58
Week 203.40 ± 1.304.08 ± 1.54
Week 223.43 ± 1.344.04 ± 1.60
Week 243.41 ± 1.314.06 ± 1.60
Week 263.41 ± 1.344.06 ± 1.60
Week 283.43 ± 1.344.02 ± 1.64
Week 303.44 ± 1.364.00 ± 1.66
Week 323.46 ± 1.373.98 ± 1.68
Week 343.47 ± 1.363.94 ± 1.71
Week 363.48 ± 1.393.94 ± 1.71
Week 383.45 ± 1.383.94 ± 1.71
Week 403.45 ± 1.383.92 ± 1.72
Week 423.45 ± 1.383.92 ± 1.72
Week 443.45 ± 1.383.94 ± 1.71
Week 463.46 ± 1.373.94 ± 1.71
Week 483.46 ± 1.383.92 ± 1.72
Week 503.43 ± 1.383.92 ± 1.72
Week 523.42 ± 1.393.92 ± 1.72
Statistical analysis
  • Aripiprazole-Double Blind Maintenance vs Placebo-Double Blind Maintenance · Cochran-Mantel-Haenszel · p = 0.3862CMH method was based on raw mean score statistics.
  • Aripiprazole-Double Blind Maintenance vs Placebo-Double Blind Maintenance · Cochran-Mantel-Haenszel · p = 0.8861CMH method was based on raw mean score statistics.
  • Aripiprazole-Double Blind Maintenance vs Placebo-Double Blind Maintenance · Cochran-Mantel-Haenszel · p = 0.8189CMH method was based on raw mean score statistics.
  • Aripiprazole-Double Blind Maintenance vs Placebo-Double Blind Maintenance · Cochran-Mantel-Haenszel · p = 0.3689CMH method was based on raw mean score statistics.
  • Aripiprazole-Double Blind Maintenance vs Placebo-Double Blind Maintenance · Cochran-Mantel-Haenszel · p = 0.9723CMH method was based on raw mean score statistics.
  • Aripiprazole-Double Blind Maintenance vs Placebo-Double Blind Maintenance · Cochran-Mantel-Haenszel · p = 0.2985CMH method was based on raw mean score statistics.
  • Aripiprazole-Double Blind Maintenance vs Placebo-Double Blind Maintenance · Cochran-Mantel-Haenszel · p = 0.0883CMH method was based on raw mean score statistics.
  • Aripiprazole-Double Blind Maintenance vs Placebo-Double Blind Maintenance · Cochran-Mantel-Haenszel · p = 0.0228CMH method was based on raw mean score statistics.
  • Aripiprazole-Double Blind Maintenance vs Placebo-Double Blind Maintenance · Cochran-Mantel-Haenszel · p = 0.0274CMH method was based on raw mean score statistics.
  • Aripiprazole-Double Blind Maintenance vs Placebo-Double Blind Maintenance · Cochran-Mantel-Haenszel · p = 0.0135CMH method was based on raw mean score statistics.
  • Aripiprazole-Double Blind Maintenance vs Placebo-Double Blind Maintenance · Cochran-Mantel-Haenszel · p = 0.0059CMH method was based on raw mean score statistics.
  • Aripiprazole-Double Blind Maintenance vs Placebo-Double Blind Maintenance · Cochran-Mantel-Haenszel · p = 0.0076CMH method was based on raw mean score statistics.
  • Aripiprazole-Double Blind Maintenance vs Placebo-Double Blind Maintenance · Cochran-Mantel-Haenszel · p = 0.0065CMH method was based on raw mean score statistics.
  • Aripiprazole-Double Blind Maintenance vs Placebo-Double Blind Maintenance · Cochran-Mantel-Haenszel · p = 0.0175CMH method was based on raw mean score statistics.
  • Aripiprazole-Double Blind Maintenance vs Placebo-Double Blind Maintenance · Cochran-Mantel-Haenszel · p = 0.0107CMH method was based on raw mean score statistics.
  • Aripiprazole-Double Blind Maintenance vs Placebo-Double Blind Maintenance · Cochran-Mantel-Haenszel · p = 0.0118CMH method was based on raw mean score statistics.
  • Aripiprazole-Double Blind Maintenance vs Placebo-Double Blind Maintenance · Cochran-Mantel-Haenszel · p = 0.0232CMH method was based on raw mean score statistics.
  • Aripiprazole-Double Blind Maintenance vs Placebo-Double Blind Maintenance · Cochran-Mantel-Haenszel · p = 0.0337CMH method was based on raw mean score statistics.
  • Aripiprazole-Double Blind Maintenance vs Placebo-Double Blind Maintenance · Cochran-Mantel-Haenszel · p = 0.0507CMH method was based on raw mean score statistics.
  • Aripiprazole-Double Blind Maintenance vs Placebo-Double Blind Maintenance · Cochran-Mantel-Haenszel · p = 0.0791CMH method was based on raw mean score statistics.
  • Aripiprazole-Double Blind Maintenance vs Placebo-Double Blind Maintenance · Cochran-Mantel-Haenszel · p = 0.0898CMH method was based on raw mean score statistics.
  • Aripiprazole-Double Blind Maintenance vs Placebo-Double Blind Maintenance · Cochran-Mantel-Haenszel · p = 0.0686CMH method was based on raw mean score statistics.
  • Aripiprazole-Double Blind Maintenance vs Placebo-Double Blind Maintenance · Cochran-Mantel-Haenszel · p = 0.0833CMH method was based on raw mean score statistics.
  • Aripiprazole-Double Blind Maintenance vs Placebo-Double Blind Maintenance · Cochran-Mantel-Haenszel · p = 0.0824CMH method was based on raw mean score statistics.
  • Aripiprazole-Double Blind Maintenance vs Placebo-Double Blind Maintenance · Cochran-Mantel-Haenszel · p = 0.0686CMH method was based on raw mean score statistics.
  • Aripiprazole-Double Blind Maintenance vs Placebo-Double Blind Maintenance · Cochran-Mantel-Haenszel · p = 0.0737CMH method was based on raw mean score statistics.
  • Aripiprazole-Double Blind Maintenance vs Placebo-Double Blind Maintenance · Cochran-Mantel-Haenszel · p = 0.0893CMH method was based on raw mean score statistics.
  • Aripiprazole-Double Blind Maintenance vs Placebo-Double Blind Maintenance · Cochran-Mantel-Haenszel · p = 0.0706CMH method was based on raw mean score statistics.
  • Aripiprazole-Double Blind Maintenance vs Placebo-Double Blind Maintenance · Cochran-Mantel-Haenszel · p = 0.0657CMH method was based on raw mean score statistics.
Other pre-specifiedMean Change From Baseline to Endpoint in PANSS Positive Subscale.

The PANSS consisted of 3 subscales were a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicated (absence of symptoms) and a score of 7 indicated (extremely severe symptoms). The 7 positive symptom constructs were delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. The PANSS Total Score ranged from 30 (best possible outcome) to 210 (worst possible outcome).

Time frame:
Baseline to Week 52/End of Phase 3 visit.
Reported as:
Mean · Units on a scale
Mean Change From Baseline to Endpoint in PANSS Positive Subscale.
Units on a scaleAripiprazole-Double Blind MaintenancePlacebo-Double Blind Maintenance
Week 1 (Aripiprazole N= 95, Placebo N= 45)0.08 ± 1.840.07 ± 2.41
Week 20.09 ± 2.05-0.04 ± 2.87
Week 30.01 ± 2.360.56 ± 3.34
Week 4-0.12 ± 2.650.58 ± 3.80
Week 6-0.20 ± 2.901.10 ± 4.85
Week 8-0.19 ± 3.231.56 ± 5.11
Week 10-0.16 ± 3.281.63 ± 5.45
Week 120.23 ± 3.581.96 ± 5.78
Week 140.28 ± 3.772.27 ± 6.03
Week 160.32 ± 3.772.17 ± 6.05
Week 180.24 ± 3.982.15 ± 6.14
Week 200.18 ± 4.002.44 ± 6.32
Week 220.39 ± 4.122.60 ± 6.44
Week 240.38 ± 4.232.65 ± 6.36
Week 260.22 ± 4.232.58 ± 6.45
Week 280.17 ± 4.282.56 ± 6.51
Week 300.24 ± 4.432.60 ± 6.59
Week 320.22 ± 4.412.71 ± 6.64
Week 340.18 ± 4.452.58 ± 6.54
Week 360.29 ± 4.452.48 ± 6.60
Week 380.22 ± 4.552.46 ± 6.63
Week 400.27 ± 4.562.44 ± 6.69
Week 420.24 ± 4.522.35 ± 6.73
Week 440.27 ± 4.522.33 ± 6.76
Week 460.21 ± 4.522.42 ± 6.69
Week 480.30 ± 4.532.29 ± 6.77
Week 500.20 ± 4.522.33 ± 6.75
Week 520.16 ± 4.552.31 ± 6.77
Other pre-specifiedMean Change From Baseline to Endpoint in PANSS Negative Subscale.

The PANSS consisted of 3 subscales were a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicated (absence of symptoms) and a score of 7 indicated (extremely severe symptoms). The 7 negative symptom constructs were blunted affect, emotional withdrawal, poor rapport, passive apathetic withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation and stereotyped thinking. The PANSS Total Score ranged from 30 (best possible outcome) to 210 (worst possible outcome).

Time frame:
Baseline to Week 52/End of Phase 3 visit.
Reported as:
Mean · Units on a scale
Mean Change From Baseline to Endpoint in PANSS Negative Subscale.
Units on a scaleAripiprazole-Double Blind MaintenancePlacebo-Double Blind Maintenance
Week 1 (Aripiprazole N= 95, Placebo N= 45)0.03 ± 1.57-0.09 ± 1.40
Week 2-0.07 ± 1.68-0.23 ± 2.35
Week 3-0.39 ± 1.890.48 ± 3.17
Week 4-0.27 ± 2.120.44 ± 3.41
Week 6-0.42 ± 2.370.90 ± 3.57
Week 8-0.41 ± 2.370.77 ± 3.76
Week 10-0.33 ± 2.470.71 ± 3.82
Week 12-0.38 ± 2.910.79 ± 4.47
Week 14-0.41 ± 3.131.15 ± 4.63
Week 16-0.51 ± 3.311.19 ± 4.77
Week 18-0.47 ± 3.451.19 ± 4.75
Week 20-0.47 ± 3.541.10 ± 4.93
Week 22-0.43 ± 3.551.06 ± 5.26
Week 24-0.42 ± 3.540.79 ± 5.41
Week 26-0.54 ± 3.600.81 ± 5.43
Week 28-0.51 ± 3.630.83 ± 5.43
Week 30-0.56 ± 3.570.67 ± 5.55
Week 32-0.52 ± 3.600.98 ± 5.89
Week 34-0.64 ± 3.680.56 ± 5.61
Week 36-0.47 ± 3.710.65 ± 5.69
Week 38-0.62 ± 3.700.54 ± 5.84
Week 40-0.64 ± 3.780.54 ± 5.78
Week 42-0.77 ± 3.790.42 ± 5.75
Week 44-0.72 ± 3.870.46 ± 5.76
Week 46-0.68 ± 3.840.35 ± 5.83
Week 48-0.73 ± 3.830.33 ± 5.88
Week 50-0.80 ± 3.840.29 ± 5.96
Week 52-0.78 ± 3.810.40 ± 5.87
Other pre-specifiedMean Change From Baseline to Endpoint in Children's Global Assessment Scale (CGAS).

The CGAS was developed by Schaffer and colleagues to provide a global measure of severity of disturbance in children and adolescents. The CGAS is a rating scale for evaluating the overall functioning of a participant during a specified time period on a continuum from psychological or psychiatric sickness to health. The CGAS is a valid and reliable tool for rating a child's general level of functioning on a health-illness continuum. CGAS score (range 1-100) was a single item score for rating a child's general level of functioning on a health-illness continuum, with higher scores represented better functioning.

Time frame:
Baseline to Week 52/End of Phase 3 visit.
Reported as:
Mean · Units on a scale
Mean Change From Baseline to Endpoint in Children's Global Assessment Scale (CGAS).
Units on a scaleAripiprazole-Double Blind MaintenancePlacebo-Double Blind Maintenance
Week 1 (Aripiprazole N= 95, Placebo N= 45)0.00 ± 2.74-0.09 ± 2.02
Week 2-0.10 ± 3.90-0.31 ± 4.03
Week 30.35 ± 4.36-1.04 ± 7.21
Week 40.29 ± 5.22-1.23 ± 7.78
Week 60.40 ± 6.01-2.08 ± 9.14
Week 80.98 ± 6.90-2.40 ± 9.93
Week 101.11 ± 7.47-2.31 ± 11.63
Week 121.08 ± 8.21-2.85 ± 11.40
Week 141.06 ± 8.49-3.52 ± 12.40
Week 161.57 ± 8.69-2.69 ± 12.96
Week 181.55 ± 9.41-2.90 ± 13.07
Week 201.28 ± 9.88-4.06 ± 14.84
Week 221.17 ± 10.15-3.77 ± 15.05
Week 241.33 ± 10.33-3.67 ± 15.20
Week 261.61 ± 10.37-3.69 ± 15.29
Week 281.73 ± 10.73-3.75 ± 15.26
Week 301.92 ± 10.89-3.44 ± 15.45
Week 321.86 ± 11.03-3.33 ± 15.47
Week 342.05 ± 11.19-3.00 ± 15.85
Week 361.87 ± 11.41-3.10 ± 15.70
Week 382.00 ± 11.59-2.85 ± 15.95
Week 401.90 ± 11.68-2.85 ± 15.99
Week 421.90 ± 11.74-2.69 ± 16.17
Week 441.83 ± 11.86-2.67 ± 16.18
Week 462.13 ± 11.74-2.67 ± 16.17
Week 482.17 ± 11.79-2.40 ± 16.42
Week 502.29 ± 11.74-2.31 ± 16.51
Week 522.35 ± 11.85-2.25 ± 16.58

Adverse events

Collected over AEs were recorded from the time the ICF was signed (with 4-Week Post-Trial Follow-up).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aripiprazole-Conversion Phase—0/186 (0%)52/186 (28%)
Arpiprazole-Stabilization Phase—4/183 (2.2%)56/183 (30.6%)
Aripiprazole-Double Blind Maintenance Treatment—3/98 (3.1%)41/98 (41.8%)
Placebo-Double Blind Maintenance Treatment—6/48 (12.5%)25/48 (52.1%)
Most frequent serious events
Most frequent serious events
EventAripiprazole-Conversion PhaseArpiprazole-Stabilization PhaseAripiprazole-Double Blind Maintenance TreatmentPlacebo-Double Blind Maintenance Treatment
SchizophreniaPsychiatric disorders0/1862/1831/985/48
Psychotic disorderPsychiatric disorders0/1861/1832/981/48
NeutropeniaBlood and lymphatic system disorders0/1861/1830/980/48
Most frequent other events
Most frequent other events
EventAripiprazole-Conversion PhaseArpiprazole-Stabilization PhaseAripiprazole-Double Blind Maintenance TreatmentPlacebo-Double Blind Maintenance Treatment
InsomniaPsychiatric disorders16/18614/1835/989/48
SchizophreniaPsychiatric disorders0/1860/1839/988/48
Weight increasedInvestigations0/18613/1838/985/48
SomnolenceNervous system disorders19/18612/1830/980/48
HeadacheNervous system disorders12/18613/1836/984/48
Psychotic disorderPsychiatric disorders0/1860/1837/984/48
TremorNervous system disorders0/18613/1834/984/48
AkathisiaNervous system disorders11/18614/1833/983/48
NasopharyngitisInfections and infestations0/1860/1837/981/48
NauseaGastrointestinal disorders0/1860/1831/983/48

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Aripiprazole-Double Blind MaintenancePlacebo-Double Blind MaintenanceTotal
Male15.3 ± 1.315.6 ± 1.115.4 ± 1.2
Female15.4 ± 1.115.3 ± 1.015.3 ± 1.1
Sex: Female, Male
Sex: Female, Male(Participants)Aripiprazole-Double Blind MaintenancePlacebo-Double Blind MaintenanceTotal
Female361450
Male623496
08

Study locations

52 sites
  • Study Site
    Downy, California 90241, United States
  • Study Site
    Glendale, California 91204, United States
  • Study Site
    Miami Springs, Florida 33166, United States
  • Study Site
    Miami, Florida 33155, United States
  • Study Site
    Atlanta, Georgia 30308, United States
  • Study Site
    Bloomfield Hills, Michigan 48302, United States
  • Study Site
    Chapel Hill, North Carolina 27517, United States
  • Study Site
    Bothell, Washington 98011, United States
  • Study Site
    Vijayawada, Andhra Pradesh 520002, India
  • Study Site
    Visakhapatnam, Andhra Pradesh 530017, India
  • Study Site
    Raipur, Chhattisgarh 492001, India
  • Study Site
    Maninagar, Ahmedabad, Gujarat 380008, India
  • Study Site
    Aurangabad, Maharashtra 431005, India
  • Study Site
    Wardha, Maharastra 442004, India
  • Study Site
    Chennai, Tamil Nadu 600003, India
  • Study Site
    Madurai, Tamil Nadu 625020, India
  • Study Site
    Lucknow, Uttar Pradesh 226003, India
  • Study Site
    Varanasi, Uttar Pradesh 221005, India
  • Study Site
    Guntur, 522001, India
  • Study Site
    Ipoh, Perak 30450, Malaysia
  • Study Site
    Batu Caves, Selangor darul Ehsan 68100, Malaysia
  • Study Site
    Kuala Lumpur, Wilayah Persekutuan 50603, Malaysia
  • Study Site
    Johor, 81200, Malaysia
  • Study Site
    Dasmarinas City, Cavite 4114, Philippines
  • Study Site
    Bajada, Davao City 8000, Philippines
  • Study Site
    Manila City, Metro Manila 1000, Philippines
  • Study Site
    Iloilo City, 5000, Philippines
  • Study Site
    Mandaluyong City, 1553, Philippines
  • Study Site
    Cluj-Napoca, Cluj 400084, Romania
  • Study Site
    Craiova, Dolj 200620, Romania
  • Study Site
    Timisoara, Timis 300239, Romania
  • Study Site
    Bucharest, 041914, Romania
  • Study Site
    Iasi, 700282, Romania
  • Study Site
    Arkhangelsk, 163530, Russian Federation
  • Study Site
    Ekaterinburg, 620030, Russian Federation
  • Study Site
    Kazan, 420061, Russian Federation
  • Study Site
    Lipetsk, 399313, Russian Federation
  • Study Site
    Moscow, 124617, Russian Federation
  • Study Site
    Moscow, 127083, Russian Federation
  • Study Site
    Nizhniy Novgorod, 603155, Russian Federation
  • Study Site
    Novosibirsk, 630091, Russian Federation
  • Study Site
    Orenburg, 460000, Russian Federation
  • Study Site
    Petrozavodsk, 185001, Russian Federation
  • Study Site
    Saratov, 410028, Russian Federation
  • Study Site
    St. Petersburg, 190005, Russian Federation
  • Study Site
    St. Petersburg, 197376, Russian Federation
  • Study Site
    Tomsk, 634014, Russian Federation
  • Study Site
    Tonnelnyi Township, 357034, Russian Federation
  • Study Site
    Yaroslavl, 150003, Russian Federation
  • Study Site
    Kaohsiung County, 833, Taiwan
  • Study Site
    Taipei City, 110, Taiwan
  • Study Site
    Taoyuan County, 333, Taiwan
09

References and documents

Publications

  • Correll CU, Kohegyi E, Zhao C, Baker RA, McQuade R, Salzman PM, Sanchez R, Nyilas M, Carson W. Oral Aripiprazole as Maintenance Treatment in Adolescent Schizophrenia: Results From a 52-Week, Randomized, Placebo-Controlled Withdrawal Study. J Am Acad Child Adolesc Psychiatry. 2017 Sep;56(9):784-792. doi: 10.1016/j.jaac.2017.06.013. Epub 2017 Jul 8. PubMed 28838583 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2011, a primary completion of Nov 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2015, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2010
First posted
Jun 23, 2010
Start
Jul 2011
Primary completionActual
Nov 2013
CompletionActual
Dec 2013
Results first posted
Apr 2, 2015
Last update
Apr 2, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01149655
Responsible party
Sponsor
First posted
Jun 23, 2010
Start date
Jul 2011
Primary completion
Nov 2013
Completion
Dec 2013
Results posted
Apr 2, 2015
Last update
Apr 2, 2015

Study contacts

Eva Kohegyi, MD
study director · Otsuka Pharmaceutical Development and Commercialization, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aripiprazole

Start the discussion